688302 海创药业
交易中 05-30 10:10:43
资讯
新帖
简况
西南证券:给予海创药业买入评级
证券之星 · 05-25
西南证券:给予海创药业买入评级
西南证券给予海创药业买入评级 德恩鲁胺NDA审评中 在研管线加速推进
每日经济新闻 · 05-25
西南证券给予海创药业买入评级 德恩鲁胺NDA审评中 在研管线加速推进
海创药业(688302)5月24日主力资金净卖出898.57万元
证券之星 · 05-25
海创药业(688302)5月24日主力资金净卖出898.57万元
海创药业:董事易宇辞任
每经网 · 05-19
海创药业:董事易宇辞任
5月19日海创药业-U涨5.10%,鹏华医药科技股票A基金重仓该股
证券之星 · 05-19
5月19日海创药业-U涨5.10%,鹏华医药科技股票A基金重仓该股
海创药业(688302)5月17日主力资金净卖出279.40万元
证券之星 · 05-18
海创药业(688302)5月17日主力资金净卖出279.40万元
全球最权威创新药大会之一将召开,多家A股公司将亮相
华尔街见闻 · 05-17
全球最权威创新药大会之一将召开,多家A股公司将亮相
海创药业(688302)5月16日主力资金净卖出869.31万元
证券之星 · 05-17
海创药业(688302)5月16日主力资金净卖出869.31万元
东方财富证券:给予海创药业增持评级
证券之星 · 05-16
东方财富证券:给予海创药业增持评级
5月16日海创药业-U涨6.74%,鹏华医药科技股票A基金重仓该股
证券之星 · 05-16
5月16日海创药业-U涨6.74%,鹏华医药科技股票A基金重仓该股
东方财富证券给予海创药业增持评级 2022年报点评:核心产品商业化在即 研发管线获多个里程碑
每日经济新闻 · 05-16
东方财富证券给予海创药业增持评级 2022年报点评:核心产品商业化在即 研发管线获多个里程碑
【风口解读】医药板块活跃海创药业涨超6%,龙头回购公募加仓,机构提示时机到了!
泡财经 · 05-16
【风口解读】医药板块活跃海创药业涨超6%,龙头回购公募加仓,机构提示时机到了!
海创药业(688302)5月12日主力资金净卖出170.85万元
证券之星 · 05-13
海创药业(688302)5月12日主力资金净卖出170.85万元
5月12日海创药业-U涨5.76%,鹏华医药科技股票A基金重仓该股
证券之星 · 05-12
5月12日海创药业-U涨5.76%,鹏华医药科技股票A基金重仓该股
海创药业-U涨5.76%,西南证券一个月前给出“买入”评级,目标价77.70元
证券之星 · 05-12
海创药业-U涨5.76%,西南证券一个月前给出“买入”评级,目标价77.70元
海创药业发布一季度业绩,净亏损7537万元
智通财经 · 04-28
海创药业发布一季度业绩,净亏损7537万元
海创药业(688302.SH)发布2022年度业绩,净亏损3.02亿元
智通财经 · 04-27
海创药业(688302.SH)发布2022年度业绩,净亏损3.02亿元
图解海创药业年报:第四季度单季净利润同比增17.99%
证券之星 · 04-27
图解海创药业年报:第四季度单季净利润同比增17.99%
加载更多
公司概况
公司名称:
海创药业股份有限公司
所属行业:
医药制造业
上市日期:
2022-04-12
主营业务:
海创药业股份有限公司是一家基于氘代技术和PROTAC靶向蛋白降解等技术平台,以开发具有重大临床需求的Best-in-class(同类最佳)、First-in-class(国际首创)药物为目标的国际化创新药企业。公司的主要产品为肿瘤、代谢性疾病药品。公司在肿瘤和代谢性疾病领域重点布局,重点搭建了氘代药物研发平台、PROTAC靶向蛋白降解技术平台、靶向药物发现与验证平台与先导化合物优化筛选平台,形成了较强的研发优势和丰富的技术储备。
发行价格:
42.92
{"stockData":{"symbol":"688302","market":"SH","secType":"STK","nameCN":"海创药业","latestPrice":67.7,"timestamp":1685412643000,"preClose":68.85,"halted":0,"volume":105390,"delay":0,"floatShares":23769600,"shares":99015600,"eps":-2.9287,"marketStatus":"交易中","marketStatusCode":2,"change":-1.15,"latestTime":"05-30 10:10:43","open":68.7,"high":69.72,"low":67.5,"amount":7207000,"amplitude":0.0322,"askPrice":67.92,"askSize":5,"bidPrice":67.7,"bidSize":17,"shortable":0,"etf":0,"ttmEps":-2.9287,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1685417400000},"adr":0,"adjPreClose":68.85,"symbolType":"stock_kcb","highLimit":75.74,"lowLimit":61.96,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":99015598,"pbRate":4.46,"roa":"--","roe":"--","epsLYR":-3.32,"committee":0.45679,"marketValue":6703000000,"floatMarketCap":1609000000,"peRate":-23.116059,"changeRate":-0.0167,"turnoverRate":0.0044,"status":1},"requestUrl":"/m/hq/s/688302","defaultTab":"news","newsList":[{"id":"2338431132","title":"西南证券:给予海创药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2338431132","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2338431132?lang=zh_CN&edition=full","pubTime":"2023-05-25 11:20","pubTimestamp":1684984835,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023052500015892.shtml","is_publish_highlight":false},{"id":"2338724139","title":"西南证券给予海创药业买入评级 德恩鲁胺NDA审评中 在研管线加速推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2338724139","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2338724139?lang=zh_CN&edition=full","pubTime":"2023-05-25 10:02","pubTimestamp":1684980153,"startTime":"0","endTime":"0","summary":"西南证券05月25日发布研报称,给予海创药业(688302.SH,最新价:69.31元)买入评级。评级理由主要包括:1)德恩鲁胺NDA获受理,有望成为国内获批转移性去势抵抗性前列腺癌;2)URAT1抑制剂和ARPROTAC产品研发加速推进;3)PROTAC等技术平台奠定持续自主创新能力,多款临床阶段产品值得期待。风险提示:研发或审评审批进展不及预期风险,市场竞争加剧风险,医药行业政策风险等。AI点评:海创药业近一个月获得2份券商研报关注,增持2家。文章来源:每日经济新闻原标题:西南证券给予海创药业买入评级,德恩鲁胺NDA审评中,在研管线加速推进","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023052510090483d6cc3d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023052510090483d6cc3d&s=b","is_publish_highlight":false},{"id":"2338418084","title":"海创药业(688302)5月24日主力资金净卖出898.57万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2338418084","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2338418084?lang=zh_CN&edition=full","pubTime":"2023-05-25 07:52","pubTimestamp":1684972346,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023052500007895.shtml","is_publish_highlight":false},{"id":"2336511514","title":"海创药业:董事易宇辞任","url":"https://stock-news.laohu8.com/highlight/detail?id=2336511514","media":"每经网","top":-1,"share":"https://www.laohu8.com/m/news/2336511514?lang=zh_CN&edition=full","pubTime":"2023-05-19 19:28","pubTimestamp":1684495738,"startTime":"0","endTime":"0","summary":"海创药业 5月19日晚间发布公告称,易宇女士因个人工作安排原因申请辞去公司第一届董事会董事职务,易宇女士辞职后将不再担任公司任何职务。海创药业的总经理、董事长均是YUANWEI CHEN(陈元伟),男,60岁,学历背景为博士。截至发稿,海创药业市值为73亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202305191939378235e0d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202305191939378235e0d0&s=b","is_publish_highlight":false},{"id":"2336591279","title":"5月19日海创药业-U涨5.10%,鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2336591279","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2336591279?lang=zh_CN&edition=full","pubTime":"2023-05-19 15:34","pubTimestamp":1684481646,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023051900017820.shtml","is_publish_highlight":false},{"id":"2336325033","title":"海创药业(688302)5月17日主力资金净卖出279.40万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2336325033","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2336325033?lang=zh_CN&edition=full","pubTime":"2023-05-18 08:24","pubTimestamp":1684369467,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023051800008388.shtml","is_publish_highlight":false},{"id":"2336325627","title":"全球最权威创新药大会之一将召开,多家A股公司将亮相","url":"https://stock-news.laohu8.com/highlight/detail?id=2336325627","media":"华尔街见闻","top":-1,"share":"https://www.laohu8.com/m/news/2336325627?lang=zh_CN&edition=full","pubTime":"2023-05-17 16:04","pubTimestamp":1684310685,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023051716031384719b65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023051716031384719b65&s=b","is_publish_highlight":false},{"id":"2336433763","title":"海创药业(688302)5月16日主力资金净卖出869.31万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2336433763","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2336433763?lang=zh_CN&edition=full","pubTime":"2023-05-17 08:12","pubTimestamp":1684282336,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023051700009215.shtml","is_publish_highlight":false},{"id":"2335879743","title":"东方财富证券:给予海创药业增持评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2335879743","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2335879743?lang=zh_CN&edition=full","pubTime":"2023-05-16 17:17","pubTimestamp":1684228654,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023051600024571.shtml","is_publish_highlight":false},{"id":"2335875230","title":"5月16日海创药业-U涨6.74%,鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2335875230","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2335875230?lang=zh_CN&edition=full","pubTime":"2023-05-16 16:43","pubTimestamp":1684226635,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023051600023068.shtml","is_publish_highlight":false},{"id":"2335875665","title":"东方财富证券给予海创药业增持评级 2022年报点评:核心产品商业化在即 研发管线获多个里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=2335875665","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2335875665?lang=zh_CN&edition=full","pubTime":"2023-05-16 15:55","pubTimestamp":1684223754,"startTime":"0","endTime":"0","summary":"东方财富证券05月16日发布研报称,给予海创药业(688302.SH,最新价:73.35元)增持评级。评级理由主要包括:1)持续加大研发投入,具备丰富的技术储备;2)核心产品HC-1119即将商业化,PROTACHP518为国内首个进入临床阶;3)公司具备国际化竞争力,同步开发国际化临床及商业合作。风险提示:审批及研发进展不及预期;行业竞争加剧风险。AI点评:海创药业近一个月获得2份券商研报关注,增持2家。文章来源:每日经济新闻原标题:东方财富证券给予海创药业增持评级,2022年报点评:核心产品商业化在即,研发管线获多个里程碑","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202305161629388227c88b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202305161629388227c88b&s=b","is_publish_highlight":false},{"id":"2335587803","title":"【风口解读】医药板块活跃海创药业涨超6%,龙头回购公募加仓,机构提示时机到了!","url":"https://stock-news.laohu8.com/highlight/detail?id=2335587803","media":"泡财经","top":-1,"share":"https://www.laohu8.com/m/news/2335587803?lang=zh_CN&edition=full","pubTime":"2023-05-16 15:54","pubTimestamp":1684223692,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023051615551883c0c9df&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023051615551883c0c9df&s=b","is_publish_highlight":false},{"id":"2335902536","title":"海创药业(688302)5月12日主力资金净卖出170.85万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2335902536","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2335902536?lang=zh_CN&edition=full","pubTime":"2023-05-13 07:40","pubTimestamp":1683934855,"startTime":"0","endTime":"0","summary":"截至2023年5月12日收盘,海创药业报收于70.31元,上涨5.76%,换手率4.08%,成交量9688.0手,成交额6649.72万元。近5日资金流向一览见下表:海创药业融资融券信息显示,融资方面,当日融资买入222.28万元,融资偿还298.84万元,融资净偿还76.56万元。根据近五年财报数据,证券之星估值分析工具显示,海创药业行业内竞争力的护城河一般,盈利能力较差,营收成长性较差。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023051300009373.shtml","is_publish_highlight":false},{"id":"2334106222","title":"5月12日海创药业-U涨5.76%,鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2334106222","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2334106222?lang=zh_CN&edition=full","pubTime":"2023-05-12 16:44","pubTimestamp":1683881067,"startTime":"0","endTime":"0","summary":"5月12日海创药业-U涨5.76%,收盘报70.31元,换手率4.08%,成交量9688.0手,成交额6649.72万元。重仓海创药业-U的前十大公募基金请见下表:该股最近90天内共有4家机构给出评级,买入评级3家,增持评级1家。根据2023Q1季报公募基金重仓股数据,重仓该股的公募基金共6家,其中持有数量最多的公募基金为鹏华医药科技股票A。鹏华医药科技股票A的前十大重仓股如下:以上内容由证券之星根据公开信息整理,与本站立场无关。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023051200022916.shtml","is_publish_highlight":false},{"id":"2334794062","title":"海创药业-U涨5.76%,西南证券一个月前给出“买入”评级,目标价77.70元","url":"https://stock-news.laohu8.com/highlight/detail?id=2334794062","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2334794062?lang=zh_CN&edition=full","pubTime":"2023-05-12 16:44","pubTimestamp":1683881062,"startTime":"0","endTime":"0","summary":"今日海创药业-U涨5.76%,收盘报70.31元。2023年3月26日,西南证券研究员杜向阳发布了对海创药业的研报《德恩鲁胺NDA获受理,未来可期》,该研报对海创药业给出“买入”评级,认为其目标价为77.7元,现价距离目标价尚有10.51%的涨幅空间。考虑海创药业研发实力强劲,氘代和PROTAC技术平台实力出众,首款创新药德恩鲁胺NDA已获受理,维持“买入”评级。海创药业-U个股概况:以上内容由证券之星根据公开信息整理,与本站立场无关。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023051200022913.shtml","is_publish_highlight":false},{"id":"2330552305","title":"海创药业发布一季度业绩,净亏损7537万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2330552305","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2330552305?lang=zh_CN&edition=full","pubTime":"2023-04-28 00:56","pubTimestamp":1682614608,"startTime":"0","endTime":"0","summary":"智通财经APP讯, 海创药业 (688302.SH)披露2023年第一季度报告,报告期公司实现营收0元;归母净利润亏损7537万元;扣非净利润亏损8261万元;基本每股收益-0.76元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230428010044842f2da8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230428010044842f2da8&s=b","is_publish_highlight":false},{"id":"2330580045","title":"海创药业(688302.SH)发布2022年度业绩,净亏损3.02亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2330580045","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2330580045?lang=zh_CN&edition=full","pubTime":"2023-04-27 21:05","pubTimestamp":1682600704,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海创药业(688302.SH)披露2022年年度报告,报告期公司实现营收165万元,上年同期0元;归母净利润亏损3.02亿元,同比收窄;扣非净利润亏损3.41亿元,同比收窄;基本每股收益-3.32元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/921956.html","is_publish_highlight":false},{"id":"2330884085","title":"图解海创药业年报:第四季度单季净利润同比增17.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2330884085","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2330884085?lang=zh_CN&edition=full","pubTime":"2023-04-27 18:41","pubTimestamp":1682592111,"startTime":"0","endTime":"0","summary":"海创药业2022年报显示,公司主营收入165.08万元,归母净利润-3.02亿元,同比上升1.52%;扣非净利润-3.41亿元,同比上升1.55%;负债率8.63%,投资收益1862.31万元,财务费用-747.57万元,毛利率53.57%。证券之星力求但不保证该信息全部或者部分内容的的准确性、完整性、有效性、及时性等,如存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023042700033219.shtml","is_publish_highlight":false}],"profile":{"ret":0,"listingDate":"2022-04-12","address":"四川省成都市武侯区高新区科园南路5号蓉药大厦1栋4层附2、3号","stockEarnings":[{"period":"1week","weight":-0.0594},{"period":"1month","weight":-0.0816},{"period":"3month","weight":0.2392},{"period":"6month","weight":0.6166},{"period":"1year","weight":1.2217},{"period":"ytd","weight":0.7076}],"companyName":"海创药业股份有限公司","boardCode":"AI0027","perCapita":"8035股","boardName":"医药制造业","registeredCapital":"9901万元","compareEarnings":[{"period":"1week","weight":-0.0228},{"period":"1month","weight":-0.0306},{"period":"3month","weight":-0.0177},{"period":"6month","weight":0.0222},{"period":"1year","weight":0.0291},{"period":"ytd","weight":0.0428}],"survey":" 海创药业股份有限公司是一家基于氘代技术和PROTAC靶向蛋白降解等技术平台,以开发具有重大临床需求的Best-in-class(同类最佳)、First-in-class(国际首创)药物为目标的国际化创新药企业。公司的主要产品为肿瘤、代谢性疾病药品。公司在肿瘤和代谢性疾病领域重点布局,重点搭建了氘代药物研发平台、PROTAC靶向蛋白降解技术平台、靶向药物发现与验证平台与先导化合物优化筛选平台,形成了较强的研发优势和丰富的技术储备。","serverTime":1685412656581,"listedPrice":42.92,"stockholders":"2958人(较上一季度减少34.19%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.13.0","shortVersion":"4.13.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海创药业(688302)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海创药业(688302)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海创药业,688302,海创药业股票,海创药业股票老虎,海创药业股票老虎国际,海创药业行情,海创药业股票行情,海创药业股价,海创药业股市,海创药业股票价格,海创药业股票交易,海创药业股票购买,海创药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海创药业(688302)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海创药业(688302)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}